CA3057849A1 - Quinoline derived small molecule inhibitors of nicotinamide n-methyltransferase (nnmt) and uses thereof - Google Patents

Quinoline derived small molecule inhibitors of nicotinamide n-methyltransferase (nnmt) and uses thereof Download PDF

Info

Publication number
CA3057849A1
CA3057849A1 CA3057849A CA3057849A CA3057849A1 CA 3057849 A1 CA3057849 A1 CA 3057849A1 CA 3057849 A CA3057849 A CA 3057849A CA 3057849 A CA3057849 A CA 3057849A CA 3057849 A1 CA3057849 A1 CA 3057849A1
Authority
CA
Canada
Prior art keywords
nnmt
cations
cation
alkyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3057849A
Other languages
English (en)
French (fr)
Inventor
Stanley Watowich
Harshini NEELAKANTAN
Stanton Mchardy
Hua-yu WANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System filed Critical The University of Texas System
Publication of CA3057849A1 publication Critical patent/CA3057849A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/10—Quaternary compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3057849A 2017-03-30 2018-03-29 Quinoline derived small molecule inhibitors of nicotinamide n-methyltransferase (nnmt) and uses thereof Pending CA3057849A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762479256P 2017-03-30 2017-03-30
US62/479,256 2017-03-30
US201762559417P 2017-09-15 2017-09-15
US62/559,417 2017-09-15
PCT/US2018/025134 WO2018183668A1 (en) 2017-03-30 2018-03-29 Quinoline derived small molecule inhibitors of nicotinamide n-methyltransferase (nnmt) and uses thereof

Publications (1)

Publication Number Publication Date
CA3057849A1 true CA3057849A1 (en) 2018-10-04

Family

ID=63676960

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3057849A Pending CA3057849A1 (en) 2017-03-30 2018-03-29 Quinoline derived small molecule inhibitors of nicotinamide n-methyltransferase (nnmt) and uses thereof

Country Status (6)

Country Link
US (2) US11401243B2 (enExample)
EP (1) EP3600317A4 (enExample)
JP (1) JP7359439B2 (enExample)
AU (1) AU2018244463B2 (enExample)
CA (1) CA3057849A1 (enExample)
WO (1) WO2018183668A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3057849A1 (en) * 2017-03-30 2018-10-04 The Board Of Regents Of The University Of Texas System Quinoline derived small molecule inhibitors of nicotinamide n-methyltransferase (nnmt) and uses thereof
ES2963560T3 (es) 2019-08-06 2024-03-27 Lilly Co Eli Compuesto piramidin-5-carboxamida
CN114272236A (zh) * 2020-09-27 2022-04-05 南京施江医药科技有限公司 用于判断线粒体氧化磷酸化通路抑制剂抗癌效果的标志物
CN114644626A (zh) * 2020-12-18 2022-06-21 南京施江医药科技有限公司 一种苯环类化合物及其应用
AU2023247721A1 (en) * 2022-03-31 2024-11-14 Shanghai Shijiang Biotechnology Co., Ltd Aromatic ring compound and use thereof
CN116969885A (zh) * 2023-08-01 2023-10-31 上海升德医药科技有限公司 一种5-氨基-1-烷基喹啉卤代物的合成工艺
TW202545926A (zh) 2024-01-12 2025-12-01 瑞典商阿斯特捷利康公司 作為菸鹼醯胺ｎ—甲基轉移酶抑制劑的哌啶衍生物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB846611A (en) * 1958-02-07 1960-08-31 Ici Ltd Nitroquinolones
FR1588846A (enExample) * 1965-07-25 1970-03-16
US4035367A (en) * 1974-09-09 1977-07-12 Sandoz, Inc. Hydroxyalkyl-substituted-amino-quinolines
US4431774A (en) * 1981-09-14 1984-02-14 Ciba-Geigy Corporation Process for the curing of stoving lacquers
US5817520A (en) * 1991-12-20 1998-10-06 Oxis International S.A. Spectrophotometric methods for assaying total mercaptans, reduced glutathione (GSH) and mercaptans other than GSH in an aqueous medium reagents and kits for implementing same
DE10130144A1 (de) * 2001-06-22 2003-01-02 Wella Ag 1-Benzopyran-Derivate und deren Salze enthaltende Färbemittel
US7977486B2 (en) * 2006-09-08 2011-07-12 Osaka University Quinolinium ion derivatives, process for the production of the derivatives, products made by using the same, and reduction and oxidation methods with the derivatives
WO2012041493A1 (en) * 2010-09-28 2012-04-05 Julius-Maximilians-Universität Würzburg Aminoquinolinium salts, methods of their production and their use as active agents for biotechnological and medical applications against binary toxins
BR112013028030B1 (pt) * 2011-05-03 2021-01-05 Basf Se composto, método para tingir fibras de queratina humanas, e, composição de tingimento
CA3057849A1 (en) * 2017-03-30 2018-10-04 The Board Of Regents Of The University Of Texas System Quinoline derived small molecule inhibitors of nicotinamide n-methyltransferase (nnmt) and uses thereof

Also Published As

Publication number Publication date
AU2018244463B2 (en) 2024-04-04
EP3600317A1 (en) 2020-02-05
JP2020512356A (ja) 2020-04-23
JP7359439B2 (ja) 2023-10-11
WO2018183668A1 (en) 2018-10-04
AU2018244463A1 (en) 2019-10-17
EP3600317A4 (en) 2020-12-23
US12071409B2 (en) 2024-08-27
US20230107256A1 (en) 2023-04-06
US20200102274A1 (en) 2020-04-02
US11401243B2 (en) 2022-08-02

Similar Documents

Publication Publication Date Title
US12071409B2 (en) Quinoline derived small molecule inhibitors of nicotinamide N-methyltransferase (NNMT) and uses thereof
US11583586B2 (en) Methods to induce targeted protein degradation through bifunctional molecules
Pretorius et al. Synthesis, characterization and antimalarial activity of quinoline–pyrimidine hybrids
Neelakantan et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice
Chen et al. Development of purine-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities
Alkahtani et al. Synthesis and biological evaluation of benzo [d] imidazole derivatives as potential anti-cancer agents
HUE032948T2 (en) Opioid receptor ligands and methods of using and making same
BR112013005806B1 (pt) Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
KR20160003196A (ko) ＂니코틴아미드 포스포리보실트랜스퍼라제의 억제제, 조성물, 제품 및 그의 용도＂
Zhang et al. Discovery of small molecules simultaneously targeting NAD (P) H: quinone oxidoreductase 1 and nicotinamide phosphoribosyltransferase: treatment of drug-resistant non-small-cell lung cancer
Barrows et al. Potent uncompetitive inhibitors of nicotinamide N-methyltransferase (NNMT) as in vivo chemical probes
US11453640B2 (en) Small molecules for disrupting the super elongation complex and inhibiting transcription elongation for cancer therapy
San José-Enériz et al. Epigenetic-based differentiation therapy for Acute Myeloid Leukemia
BR112012019691B1 (pt) Métodos in vitro para reduzir a atividade de uma proteína, ou para alterar a progressão do ciclo celular eucariótico, composto para a inibição de rpa, seus usos e uso de um composto a ou um sal farmaceuticamente aceitável do mesmo
CN112638881A (zh) 用于治疗转移性和化疗耐受性癌症的四氢喹啉衍生物
CN117321056A (zh) 一种芳香环类化合物及其用途
Ma et al. Structure-based discovery of a specific SHP2 inhibitor with enhanced blood–brain barrier penetration from PubChem database
Simeon et al. Discovery of Functionalized 1H-Benzo [d] imidazoles That Confer Protective Effects in a Phenotypic CLN3 Disease Patient-Derived iPSC Model
RU2717310C1 (ru) Ингибиторы альдостеронсинтазы на основе производных 2-амино-4H-пиран-3-карбонитрила
Rajabi et al. Naringenin Enhances Anti-Proliferation Effect of FMSP On K562 Human Chronic Myelogenous Leukemia Cells Via Targeting Calmodulin Signaling Pathway
Bauer Targeting reader domains of the epigenetic code
WO2025137355A1 (en) Proxy binding for screening therapeutic compounds
JP2023530734A (ja) アイソフォーム特異的アルデヒドデヒドロゲナーゼ阻害剤
WO2026062665A1 (en) Sulfonamide-based compounds and use thereof as fto inhibitors
HK40049062A (en) Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230327

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241010

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241209

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241209

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250225

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250527

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250527

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250925

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251205

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251205

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260126

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260202

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260202